BELBUCA®
(buprenorphine buccal film)
75 • 150 • 300 • 450 • 600 • 750 • 900 mcg

Why you should consider BELBUCA® for severe and persistent pain when short-acting opioids are inadequate*

INDICATION

*BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.

Limitations of Use

- Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- BELBUCA is not indicated as an as-needed (prn) analgesic.

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA®

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA

Addiction, Abuse, and Misuse

BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.

Accidental Exposure

Accidental exposure of even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine.

Risks from Concomitant Use with Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

Please see Important Safety Information and full Prescribing Information including Boxed Warning on Addiction, Abuse and Misuse and other serious risks.

As a buccal film, **BELBUCA** is different from other forms of buprenorphine

UNIQUE BEMA® TECHNOLOGY

The first and only Schedule III opioid using buprenorphine buccal film technology[1-3]

MucoAdhesive layer contains a dose of buprenorphine and adheres securely within seconds upon contact with the inside of the cheek[1,2]


Backing layer forms a barrier that helps facilitate one-way flow of medication into buccal mucosa[1,4]



For illustrative purposes only. Not the actual product or size.

FLEXIBLE DOSING OPTIONS

7 dose strengths to identify your patients' optimal dose for treating severe and persistent pain[1]



Maximum dose is 900 mcg every 12 hours. Do not exceed due to the potential for QTc interval prolongation.

- Offers more dosing options and strengths than the transdermal patch[1,5]
- Titrate BELBUCA to a dose that provides adequate analgesia and minimizes adverse reactions[1]
- **There are no head-to-head studies between BELBUCA and other opioids**

BEMA=BioErodible MucoAdhesive.

DOSING AND ADMINISTRATION

BELBUCA dosing and administration vs transdermal buprenorphine in patients with severe and persistent pain

	BELBUCA[1,6]	Transdermal buprenorphine[5,7]
Total daily dose of prior opioid*	**0-160 MME**	0-80 MME
Bioavailability	**46%-65%**	~15%
Half-life	**27.6 hours**	26 hours†
Total number of dose strengths	**7**	5
Maximum dose	**900 mcg**	20 mcg/hr
Dosing interval	**q12h**	q7d
Titration interval	**4 days**	3 days
Method of application	**Apply to inside of cheek every 12 hours. Typically dissolves in 30 minutes** Avoid eating or drinking until the film is dissolved Wait 1 hour before brushing teeth	**Apply to skin at 1 of 8 designated sites every 7 days. Do not apply to same site for 21 days** Apply to hairless or nearly hairless skin site Avoid exposure to heat (hot baths, sunbathing, hot tubs, saunas, heating pads, etc)

Table is based on information included in the full Prescribing Information for each product. **There are no head-to-head studies comparing pharmacokinetics, bioavailability, safety, and efficacy of the 2 products.**

Transdermal buprenorphine hourly dosing: 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr.

*Total daily MME of the opioid medications patients took prior to enrolling in clinical trials.
†Following patch removal.
MME=morphine milligram equivalent; q7d=every 7 days; q12h=every 12 hours.

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA® (cont'd)

CONTRAINDICATIONS

BELBUCA is contraindicated in patients with significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity (e.g., anaphylaxis) to buprenorphine.

Please see Important Safety Information and full Prescribing Information including Boxed Warning on Addiction, Abuse and Misuse and other serious risks.

BELBUCA can be prescribed with short-acting/immediate-release opioids as rescue medication[1]

BELBUCA was studied utilizing short-acting opioids as rescue medication for breakthrough pain

- BELBUCA is not contraindicated with short-acting opioids
- Patients may require additional short-acting analgesics during the taper period and titration
- Patients who experience breakthrough pain may require dosage adjustment of BELBUCA or may need rescue medication with an appropriate dose of an immediate-release analgesic

	Opioid-experienced study[8,9]	Long-term study[10,11]
Rescue medication	Use of HC/APAP 5/325 mg (PRN, no more frequently than q6h)	Use of HC/APAP 5/325 mg (PRN, no more frequently than q6h)
Analgesic taper	**4 weeks** ≤4 doses/day (1 tablet/dose)	**Up to 4 weeks** ≤4 doses/day (de novo subjects only) (1-2 tablets/dose, maximum of 4 tablets per day)
Open-label titration	**8 weeks** ≤4 doses/day (1-2 tablets/dose)	**Up to 9 weeks** ≤4 doses/day (1-2 tablets/dose, maximum of 8 tablets per day)
Treatment phase	**12 weeks** (double blind) Weeks 1-2: ≤2 doses/day (1-2 tablets/dose) Weeks 3-12: 1 dose/day (1-2 tablets/dose) **The percentage of patients using rescue medication at week 12 of the double-blind treatment period was significantly lower in the BELBUCA group than the placebo group (*P*<0.001)**	**Up to 48 weeks** (open label, all subjects) ≤4 doses/day (1-2 tablets/dose, maximum of 4 tablets per day)* **The need for rescue medication decreased from 3 tablets per day during titration to 1.1 tablets per day during the long-term treatment period on average**

*If a subject required more than 2 tablets per day on a regular basis between study visits, they could up-titrate the subject to the next dose level of buprenorphine.
HC/APAP=hydrocodone/acetaminophen; NRS=numerical rating scale; PRN=as needed; q6h=every 6 hours.

Opioid-experienced study design: The efficacy and safety of BELBUCA were evaluated in a multicenter, double-blind, placebo-controlled study in opioid-experienced patients with moderate to severe chronic low back pain. The primary objective of the study was to determine the change in mean average NRS daily pain intensity score from baseline to week 12 of the double-blind treatment period. Enriched-enrollment population included only patients who had shown a previous response to opioids. When patients achieved ≤30-mg MME for at least 3 days, they were eligible to enter the open-label dose-titration period. In all, 810 patients were dosed in the open-label titration phase of the study. Of those, 511 (63%) were able to titrate to an optimal dose by the end of the open-label titration phase. Double-blind study medication was given to 511 patients, with 254 randomized to BELBUCA and 257 to placebo. In all, 206 (81%) patients who received BELBUCA and 147 (57%) who received placebo completed the 12-week treatment phase.[1,8]

48-week, long-term safety and analgesic efficacy study design: The long-term safety, tolerability, and analgesic efficacy of BELBUCA were evaluated in an open-label, single-arm study in opioid-naive and opioid-experienced patients with moderate to severe chronic pain. The primary objective was to determine long-term safety and tolerability of BELBUCA. The open-label titration phase of the study included 506 patients; 435 entered the long-term treatment phase. Of those, 158 patients (36.3%) completed the long-term treatment phase. The majority of patients discontinued long-term treatment due to the sponsor's decision to terminate the study (n=141; 32.4%). Other reasons for study discontinuation included withdrawal by the patient (n=36; 8.3%), loss to follow-up (n=21; 4.8%), adverse events (n=17; 3.9%), protocol violation (n=12; 2.8%), and lack of efficacy (n=8; 1.8%). The most commonly reported adverse events (AEs) in the long-term treatment phase included nausea (8.3%), vomiting (5.1%), upper respiratory infections (4.8%), constipation (3.9%), back pain (3.7%), diarrhea (3.4%), nasopharyngitis (3.2%), urinary tract infection (3%), and falls (3%).[10]

There were no reports of respiratory depression in the phase 3, long-term safety study. Profound sedation, respiratory depression, coma, and death may result from the concomitant use of BELBUCA with benzodiazepines or other CNS depressants.[1,10]

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA® (cont'd)

WARNINGS AND PRECAUTIONS

Addiction, Abuse, and Misuse

- BELBUCA contains buprenorphine, a Schedule III controlled substance. As an opioid, BELBUCA exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed BELBUCA. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use.

BELBUCA® (buprenorphine buccal film)
75 • 150 • 300 • 450 • 600 • 750 • 900 mcg

Please see Important Safety Information and full Prescribing Information including Boxed Warning on Addiction, Abuse and Misuse and other serious risks.

BELBUCA has paid rates similar to the generic buprenorphine patch across all segments[12]*

Patients covered by commercial health plans[12]

- Greater than 90% commercial coverage†
  - BELBUCA is preferred by most top commercial health plans and pharmacy benefit managers, which means it has the lowest branded copays
- COPAY SAVINGS‡ available
  - Eligible, commercially insured patients may pay as little as $0 with the BELBUCA copay card‡

Patients covered by Medicare Part D

- Patients can obtain BELBUCA via prior authorization/medical exception when the correct form is used[12†]
- Appropriate patients enrolled in the Extra Help program can receive any branded medication, including BELBUCA, for less than $15[13]



Eligible, commercially insured patients may start saving today with the BELBUCA savings card.

Your appropriate patients may **pay as little as $0** for BELBUCA.‡

Ensure you are leveraging the right approval form by visiting www.CollegiumCoverage.com

Your appropriate patients may be able to save on BELBUCA.

Learn more

*Based on IQVIA FIA analysis of rolling 12-month weighted paid claims average ending March 2026.
†Managed Markets Insights and Technology (MMIT) analysis May 2026.
‡For eligible, commercial patients only. Maximum savings limit applies; patient out-of-pocket expense may vary. Please see Program Terms, Conditions, and Eligibility Criteria at www.belbuca.com/savings.

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA® (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Addiction, Abuse, and Misuse (cont'd)

- Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing BELBUCA and reassess all patients receiving BELBUCA for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as BELBUCA, but use in such patients necessitates intensive counseling about the risks and proper use of BELBUCA, along with frequent reevaluation for signs of addiction, abuse, or misuse.

Please see Important Safety Information and full Prescribing Information including Boxed Warning on Addiction, Abuse and Misuse and other serious risks.

INDICATION

BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.

Limitations of Use

- Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- BELBUCA is not indicated as an as-needed (prn) analgesic.

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA®

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA

Addiction, Abuse, and Misuse

BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.

Accidental Exposure

Accidental exposure of even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine.

Risks from Concomitant Use with Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

CONTRAINDICATIONS

BELBUCA is contraindicated in patients with significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity (e.g., anaphylaxis) to buprenorphine.

WARNINGS AND PRECAUTIONS

Addiction, Abuse, and Misuse

- BELBUCA contains buprenorphine, a Schedule III controlled substance. As an opioid, BELBUCA exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed BELBUCA. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use.
- Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing BELBUCA and reassess all patients receiving BELBUCA for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as BELBUCA, but use in such patients necessitates intensive counseling about the risks and proper use of BELBUCA, along with frequent reevaluation for signs of addiction, abuse, or misuse.
- Consider recommending or prescribing an opioid overdose reversal agent.
- Abuse or misuse of BELBUCA by swallowing may cause choking, overdose, and death.
- Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing BELBUCA. Strategies to reduce the risk include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substance authority for information on how to prevent and detect abuse or diversion of this product.

Life-Threatening Respiratory Depression

- Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents, depending on the patient's clinical status. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.
- While serious, life-threatening or fatal respiratory depression can occur at any time during the use of BELBUCA, the risk is greatest during initiation of therapy or following a dosage increase.
- To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Overestimating the dose of BELBUCA when converting patients from another opioid product may result in fatal overdose with the first dose.
- Accidental exposure to BELBUCA, especially in children, can result in respiratory depression and death due to an overdose of buprenorphine.
- Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose.
- Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper.

Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose

- Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient.
- Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program).
- There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent.
- Educate patients and caregivers on how to recognize respiratory depression, and how to use an opioid overdose reversal agent for the emergency treatment of opioid overdose. Emphasize the importance of calling 911 or getting emergency medical help, even if an opioid overdose reversal agent is administered.

Risks due to Interactions with Benzodiazepines or Other Central Nervous System Depressants

- Profound sedation, respiratory depression, coma, and death may result from the concomitant use of BELBUCA with benzodiazepines or other CNS depressants including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

BELBUCA®
(buprenorphine buccal film)
75 • 150 • 300 • 450 • 600 • 750 • 900 mcg

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA® (cont'd)

Risks due to Interactions with Benzodiazepines or Other Central Nervous System Depressants (cont'd)

- Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics.
- If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction and educate them on signs and symptoms of respiratory depression (including sedation).
- If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent.
- Advise both patients and caregivers about the risks of respiratory depression and sedation when BELBUCA is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs.

Neonatal Opioid Withdrawal Syndrome (NOWS)

- Use of BELBUCA for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of NOWS and manage accordingly. Advise pregnant women using opioids for an extended period of the risk of NOWS and ensure that appropriate treatment will be available.

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

- To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the FDA has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers.

Healthcare providers are strongly encouraged to do all of the following:

- Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain.
- Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The Patient Counseling Guide (PCG) can be obtained at this link: www.fda.gov/OpioidAnalgesicREMSPCG.
- Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them.
- Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities.

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com. The FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint.

Opioid-Induced Hyperalgesia and Allodynia

- Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.
- Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety).

Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients

- The use of BELBUCA in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.
- BELBUCA-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive, including apnea, even at recommended dosages of BELBUCA.
- Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.
- Regularly evaluate patients, particularly when initiating and titrating BELBUCA and when BELBUCA is given concomitantly with other drugs that depress respiration.

Adrenal Insufficiency

- Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include nonspecific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Severe Hypotension

- BELBUCA may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of BELBUCA. In patients with circulatory shock, BELBUCA may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of BELBUCA in patients with circulatory shock.

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness

- In patients who may be susceptible to the intracranial effects of CO_2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), BELBUCA may reduce respiratory drive, and the resultant CO_2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with BELBUCA.
- Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of BELBUCA in patients with impaired consciousness or coma.

Hepatotoxicity

- Cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving sublingual formulations of buprenorphine for the treatment of opioid dependence, both in clinical trials and in post-marketing adverse events reports. For patients at increased risk of hepatotoxicity (e.g., patients with a history of excessive alcohol intake, intravenous drug abuse or liver disease), obtain baseline liver enzyme levels and periodically reassess during treatment with BELBUCA.

Risk of Gastrointestinal Complications

- BELBUCA is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
- BELBUCA may cause spasm of the sphincter of Oddi. Opioids may cause increases in the serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- Cases of opioid-induced esophageal dysfunction (OIED) have been reported in patients taking opioids. The risk of OIED may increase as the dose and/or duration of opioids increases.
- Regularly evaluate patients for signs and symptoms of OIED (e.g., dysphagia, regurgitation, non-cardiac chest pain) and, if necessary, adjust opioid therapy as clinically appropriate.

IMPORTANT SAFETY INFORMATION ABOUT BELBUCA® (cont'd)

Increased Risk of Seizures in Patients with Seizure Disorders

- The buprenorphine in BELBUCA may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures occurring in other clinical settings associated with seizures. Regularly evaluate patients with a history of seizure disorders for worsened seizure control during BELBUCA therapy.

Dental Adverse Events

- Cases of dental caries, some severe (i.e., tooth fracture, tooth loss), have been reported following the use of transmucosal buprenorphine-containing products. Reported events include cavities, tooth decay, dental abscesses/infection, rampant caries, tooth erosion, fillings falling out, and, in some cases, total tooth loss. Treatment for these events included tooth extraction, root canal, dental surgery, as well as other restorative procedures (i.e., fillings, crowns, implants, dentures). Multiple cases were reported in individuals without any prior history of dental problems.
- Refer patients to dental care services and encourage them to have regular dental checkups while taking BELBUCA. Educate patients to seek dental care and strategies to maintain or improve oral health while being treated with transmucosal buprenorphine containing products. Strategies include, but are not limited to, gently rinsing the teeth and gums with water and then swallowing after BELBUCA has been completely dissolved in the oral mucosa. Advise patients to wait for at least one hour after taking BELBUCA before brushing teeth.

QTc Prolongation

- Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤15 msec. This QTc prolongation effect does not appear to be mediated by hERG channels. Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors. The risk of combining buprenorphine with other QT-prolonging agents is not known.
- Consider these observations in clinical decisions when prescribing BELBUCA to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia.

Anaphylactic/Allergic Reactions

- Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in post-marketing experience. The most common signs and symptoms include rashes, hives, and pruritus. Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported.

Withdrawal

- Do not rapidly reduce or abruptly discontinue BELBUCA in a patient physically dependent on opioids. When discontinuing BELBUCA in a physically dependent patient, gradually taper the dosage. Rapid tapering of buprenorphine in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain.
- Additionally, the use of BELBUCA, a partial agonist opioid analgesic, in patients who are receiving a full opioid agonist analgesic may reduce the analgesic effect and/or precipitate withdrawal symptoms. Avoid concomitant use of BELBUCA with a full opioid agonist analgesic.

Risks of Driving and Operating Machinery

- BELBUCA may impair the mental and physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to side effects of BELBUCA and know how they will react to the medication.

Risk of Overdose in Patients with Moderate or Severe Hepatic Impairment

- In a pharmacokinetic study of subjects dosed with buprenorphine sublingual tablets, buprenorphine plasma levels were found to be higher and the half-life was found to be longer in subjects with moderate and severe hepatic impairment, but not in subjects with mild hepatic impairment. For patients with severe hepatic impairment, a dose adjustment is recommended, and patients with moderate or severe hepatic impairment should be monitored for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine.

Risks of Use in Cancer Patients with Oral Mucositis

- Cancer patients with oral mucositis may absorb buprenorphine more rapidly than intended and are likely to experience higher plasma levels of the opioid. For patients with known or suspected mucositis, a dose reduction is recommended. Regularly evaluate these patients carefully for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine.

ADVERSE REACTIONS

- The most common adverse reactions (≥5%) reported by patients treated with BELBUCA in the clinical trials were nausea, constipation, headache, vomiting, fatigue, dizziness, and somnolence.

See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, accompanying this piece or at BELBUCA.com/pi.

To report SUSPECTED ADVERSE REACTIONS, contact Collegium Pharmaceutical, Inc. at 1-855-331-5615 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

REFERENCES: 1. BELBUCA [Prescribing Information]. Stoughton, MA: Collegium Pharmaceutical, Inc.; December 2025. **2.** Data on file, DOF-BL-04. Collegium Pharmaceutical, Inc.; 2015. **3.** *Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations*. US Dept of Health and Human Services, Food and Drug Administration; 1985. Accessed December 22, 2025. http://purl.access.gpo.gov/GPO/LPS1445 **4.** Hale M, et al. *Pain Manag.* 2020;10(4):213-223. **5.** BUTRANS [Prescribing Information]. Stamford, CT: Purdue Pharma L.P. December 2023. **6.** Priestley T, et al. *Pain Med.* 2018;19(10):1988-1996. **7.** Wang Y, et al. *J Clin Pharmacol.* 2016;56(10):1263-1271. **8.** Gimbel J, et al. *Pain.* 2016;157(11):2517-2526. **9.** Data on file, CSR EN3409-307. Collegium Pharmaceutical, Inc.; 2014. **10.** Hale M, et al. *J Pain Res.* 2017;10:233-240. **11.** Data on file, CSR EN3409-309. Collegium Pharmaceutical, Inc.; 2015. **12.** Managed Markets Insight & Technology, LLC (MMIT) Coverage Data as of May 2026, Data on File. **13.** Announcement of Calendar Year (CY) 2025 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. Centers for Medicare & Medicaid Services. April 1, 2024. Accessed May 5, 2026. https://www.cms.gov/files/document/2025-announcement.pdf **14.** Dowell D, et al. *MMWR Recomm Rep.* 2022;71(3):1-95. **15.** Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. US Dept of Health and Human Services; 2019. Accessed May 5, 2026. pmtf-final-report-2019-05-23.pdf (hhs.gov). **16.** VA/DoD Clinical Practice Guideline for the Use of Opioids in the Management of Chronic Pain. Version 4.0. Dept of Veterans Affairs, Dept of Defense; 2022. Accessed May 5, 2026. https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOpioidsCPG.pdf

BELBUCA®
(buprenorphine buccal film)
75 • 150 • 300 • 450 • 600 • 750 • 900 mcg

When alternative treatment options, including short-acting opioids, are inadequate...

Make **BELBUCA** your first-choice long-acting opioid for the treatment of severe and persistent pain[1]*

BUCCAL DELIVERY


The first and only Schedule III long-acting opioid using BEMA® buccal film technology to deliver buprenorphine[1-3]

PROVEN EFFICACY

Significant and sustained pain relief in opioid-experienced patients and patients who are not opioid tolerant[1]

FLEXIBLE DOSING

7 dose strengths, allowing for flexible dosing options to start patients at the right dose and titrate to the optimal dose[1]



The efficacy of BELBUCA has been evaluated in three 12-week, double-blind, placebo-controlled clinical trials in opioid-naive (Study 308, Rauck RL, et al. *Postgrad Med*. 2016) and opioid-experienced patients with moderate to severe chronic low back pain using pain scores as the primary efficacy variable. Two of these studies demonstrated efficacy in patients with low back pain. One study in low back pain did not show a statistically significant pain reduction for BELBUCA compared with placebo.

There are no head-to-head studies between BELBUCA and other opioids.

No associated CDC MME conversion factor with buprenorphine[14]

The US Department of Health & Human Services and the Department of Veterans Affairs/the Department of Defense recommend considering buprenorphine, a partial agonist, before full agonist opioids in adults with severe and persistent pain[15,16]

CDC MME guidelines and HHS and VA/DoD guidelines are for guidance only and are not a substitute for clinical decision making. Refer to your state-specific guidelines regarding MME conversions.

BEMA=BioErodible MucoAdhesive; CDC=Centers for Disease Control and Prevention, MME=morphine milligram equivalent.

INDICATION

*BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.

Limitations of Use

- Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
- BELBUCA is not indicated as an as-needed (prn) analgesic.

Please see Important Safety Information and full Prescribing Information including Boxed Warning on Addiction, Abuse and Misuse and other serious risks.

Collegium PHARMACEUTICAL

BELBUCA is a registered trademark of BioDelivery Sciences International, Inc., a wholly owned subsidiary of Collegium Pharmaceutical, Inc. Collegium Pharmaceutical and the Collegium Pharmaceutical logo are registered trademarks of Collegium Pharmaceutical, Inc.
© 2026 Collegium Pharmaceutical, Inc. All rights reserved.
PP-BEL-US-0334 10/26

BELBUCA®
(buprenorphine buccal film)
75 • 150 • 300 • 450 • 600 • 750 • 900 mcg